Intensifying tumour immunity through combination therapy

The Lancet Oncology

Volumn 13, Issue 5, 2012, Pages 440-442

  Dranoff, Glenn ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE PROSTATE ISOENZYME; CANCER VACCINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IPILIMUMAB; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN;

ADVANCED CANCER; ANTIGEN PRESENTING CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELLULAR IMMUNITY; COLITIS; DERMATITIS; DRUG MECHANISM; DRUG RESPONSE; ENDOCRINE DISEASE; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNOREGULATION; INFLAMMATORY DISEASE; LETTER; LOCAL SKIN REACTION; LYMPHOCYTE PROLIFERATION; MELANOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD MONONUCLEAR CELL; PNEUMONIA; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; TUMOR REGRESSION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CANCER VACCINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MALE; POXVIRIDAE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; VIRAL VACCINES;

EID: 84860490666     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70051-7     Document Type: Letter

References (13)

1. Frei E Curative cancer chemotherapy. Cancer Res 1985, 45:6523-6537.
2. Su F, Viros A, Milagre C, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 2012, 366:207-215.
3. van den Eertwegh AJM, Versluis J, van den Berg HP, et al. Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, published online Feb 10. 10.1016/S1470-2045(12)70007-4.
4. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012, published online Feb 10. 10.1016/S1470-2045(12)70006-2.
5. Mellman I, Coukos G, Dranoff G Cancer immunotherapy comes of age. Nature 2011, 480:480-489.
6. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
7. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723.
8. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011, 364:2517-2526.
9. Korman A, Peggs K, Allison JP Checkpoint blockade in cancer immunotherapy. Adv Immunol 2006, 90:293-335.
10. Dranoff G Experimental mouse tumour models: what can be learnt about human cancer immunology?. Nat Rev Immunol 2011, 12:61-66.
11. Kantoff PW, Schuetz TJ, Blumenstein BA, et al. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010, 28:1099-1105.
12. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colony-stimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007, 13:3883-3891.
13. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008, 105:3005-3010.